Oncomed Pharmaceuticals Downgraded to “Underperform” at Zacks (OMED)
Oncomed Pharmaceuticals (NASDAQ:OMED) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued on Tuesday. They currently have a $15.00 price target on the stock. Zacks‘s target price points to a potential downside of 16.90% from the company’s current price.
In other Oncomed Pharmaceuticals news, SVP Timothy Hoey sold 2,500 shares of the company’s stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $21.66, for a total value of $54,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. One investment analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $35.75.
Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 1.00% on Tuesday, hitting $17.87. 78,884 shares of the company’s stock traded hands. Oncomed Pharmaceuticals has a 52 week low of $12.07 and a 52 week high of $42.34. The stock has a 50-day moving average of $22.02 and a 200-day moving average of $27.08. The company’s market cap is $531.8 million.
Oncomed Pharmaceuticals (NASDAQ:OMED) last announced its earnings results on Thursday, August 7th. The company reported ($0.53) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. On average, analysts predict that Oncomed Pharmaceuticals will post $-1.17 earnings per share for the current fiscal year.
OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.
To view Zacks’ full report, visit Zacks’ official website.
Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.